VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog
← Value Add PulseIPOUp to 15.85M shares

Already-Public Actelis Networks Files New S-1 to Amend Its Equity Line With White Lion Capital

Actelis Networks, the Nasdaq-listed hybrid fiber-coax networking company, filed a Form S-1 on July 1 to re-register shares tied to an amended equity line of credit (ELOC) with White Lion Capital, after 10 million of the 10.6 million shares originally registered for the arrangement in October 2025 remained unsold. The amendment registers up to 15.85 million shares across revised ELOC shares, commitment shares and warrant shares — a dilutive financing structure for a cybersecurity-hardened networking equipment maker, rather than a new IPO.

S-1, July 1, 2026
Filing
10.64M shares, 10M unsold
Prior ELOC Registration (Oct 2025)
Up to 15.85M shares
New Registration
White Lion Capital LLC
ELOC Partner
ASNS (Nasdaq, already public)
Ticker
TC
Trace Cohen
Early-stage VC & angel · Founder, New York Venture Partners
July 1, 2026
2 min read
ShareXLinkedInEmail
KEY TAKEAWAYS FOR VCs & FOUNDERS
1

Not a new-company IPO — this is dilutive equity-line financing for an already-public micro-cap, an important distinction from most items in this IPO pipeline roundup

2

10 million of 10.6 million previously registered shares going unsold signals real difficulty finding buyers at Actelis' current market terms

3

Actelis' technology — upgrading existing copper/coax to near-fiber performance — is a genuinely useful niche for government and carrier networks avoiding costly fiber buildouts

4

Illustrates the financing reality many small-cap public networking and infrastructure companies face: ongoing dilution through equity lines rather than access to traditional follow-on markets

TC
The VC Read · Trace's TakeTrace Cohen

This filing is a useful reminder that not everything hitting EDGAR under 'S-1' is a fresh IPO story — Actelis is already public, and 10 million of 10.6 million previously registered equity-line shares going unsold over seven months tells you more about weak demand at current terms than any growth narrative. The underlying business (extending copper and coax infrastructure to near-fiber performance for government and carrier customers) is a legitimate, unglamorous niche that will keep mattering as long as full fiber buildouts remain expensive. But an amended, expanded equity line is the financing tool of a small-cap company with limited access to cleaner capital markets, not a growth signal. For LPs and public investors, ongoing ELOC dilution is worth tracking as a leading indicator of a company's real cash position, since it usually means traditional follow-on offerings weren't a realistic option at the company's current valuation.

📈 Tech IPO Tracker →

Actelis Networks, which already trades publicly on Nasdaq under the ticker ASNS, filed a new Form S-1 with the SEC on July 1, 2026 — not to go public for the first time, but to amend and re-register shares tied to an existing equity line of credit arrangement with White Lion Capital LLC. The company originally registered roughly 10.64 million shares for resale under an ELOC and PIPE arrangement effective November 28, 2025; as of July 1, 2026, 10 million of those shares remained unsold, prompting Actelis to sign Amendment No. 1 to the ELOC agreement the same day, changing purchase-notice mechanics and obligating the company to issue additional securities.

The new filing de-registers the unsold shares from the original arrangement and re-registers a combined total of up to 15.85 million shares issuable to White Lion: 6 million revised ELOC shares, 3 million amendment commitment shares, 3.85 million pre-funded warrant shares, and 3 million common warrant shares. This is dilutive financing plumbing for an already-public small-cap company, not a fresh capital-markets debut — an important distinction, since equity-line arrangements let a company draw down cash incrementally by selling shares to a single counterparty, typically at a discount to market price, in exchange for financing flexibility that traditional follow-on offerings don't provide.

Actelis Networks, headquartered in Sunnyvale, California and led by CEO Tuvia Barlev, makes hybrid fiber-and-copper-coax networking equipment that upgrades existing copper and coaxial infrastructure to near-fiber performance levels, targeting cybersecurity-hardened IoT deployments and government and carrier network customers who want to avoid the cost of laying new fiber. That niche — extending the useful life of legacy physical infrastructure rather than replacing it outright — has real utility for government and defense customers operating under budget constraints, even as broader telecom infrastructure investment increasingly favors fiber-first buildouts.

The fact that 10 million of the original 10.64 million registered shares went unsold over roughly seven months is a meaningful signal about market demand at Actelis' current terms: either pricing conditions in the ELOC arrangement weren't attractive enough to White Lion to draw down at pace, or Actelis chose not to draw on the facility as aggressively as the registration allowed. The amendment's expanded share count and revised purchase-notice mechanics suggest the company is working to make the facility more usable going forward, likely because it needs the financing flexibility an ELOC provides more than it wants to pursue a traditional, harder-to-execute follow-on offering at its current small-cap valuation.

For investors and operators in the connectivity and government-networking infrastructure space, Actelis represents a real, if underappreciated, category: companies extending the useful life of existing copper and coax infrastructure rather than requiring full fiber replacement, a genuinely cost-effective approach for budget-constrained government and carrier customers. For LPs and public-market investors already holding ASNS shares, an under-drawn equity line being amended and expanded is worth watching as an indicator of the company's ongoing capital needs and the market's appetite to absorb additional dilution.

What to watch: how quickly White Lion begins drawing down shares under the amended ELOC terms, whether Actelis' underlying networking-equipment revenue shows growth that would reduce reliance on dilutive financing going forward, and whether other small-cap public networking or infrastructure companies pursue similar equity-line amendments as traditional capital markets remain difficult for names their size.

ShareXLinkedInEmail

Originally reported by SEC EDGAR. Analysis and editorial commentary by Value Add Pulse.

← Back to Pulse

Read Next

IPO$1.68B raised, +40% debut

Bending Spoons Defies the SaaS Slump, Surges 40% on Nasdaq Debut to a Near-$26B Close

Bending Spoons priced its Nasdaq IPO at $29 per share on June 30 — above its $26-$28 marketed range — raising $1.68 billion at an $18.4 billion valuation, then closed its first trading day up roughly 40% near $25.7 billion. The Milan-based company, which buys and revitalizes aging tech brands including AOL, Evernote, Meetup and Vimeo, posted $601 million in Q1 revenue and swung to a $27.4 million profit from a $112 million loss a year earlier.

IPODirect listing filed

QumulusAI Files S-1/A for Nasdaq Direct Listing as GPU-Cloud Provider to Underserved AI Customers

QumulusAI filed a seventh S-1/A amendment on July 1 ahead of a planned Nasdaq direct listing, detailing an Atlanta-based GPU-as-a-service business built from the 2022 merger of a blockchain-hosting company and a data-center asset firm, later rebranded after acquiring The Cloud Minders in 2025. The company reported $3.4 million in quarterly revenue against a $5.5 million operating loss, is scaling toward 120 megawatts and up to 90,000 Nvidia B200/B300 GPUs, and disclosed going-concern risk in its filing.

IPO~$12.6M-$14.67M

Encore Medical Files Amended S-1 to Fund US Trials for Its Heart-Defect Closure Device

Encore Medical filed an amended S-1 on July 1 ahead of a planned NYSE American listing under ticker EMI, offering 3 million shares at an expected $5.00 each to raise roughly $12.6-14.67 million to fund US clinical trials for its catheter-delivered heart-defect closure device, which has completed more than 35,000 implants outside the United States but has not yet been approved for US sale. Underwriters BofA Securities, Goldman Sachs and Morgan Stanley are jointly leading the offering.

@Trace_Cohen·t@nyvp.com